How is the Retinal Vein Occlusion Treatment Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the retinal vein occlusion treatment market?
In recent times, the industry for retinal vein occlusion treatment has seen impressive growth. The market, valued at $2.26 billion in 2024, is predicted to increase to $2.43 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.3%. This robust expansion in the historical timeframe is credited to various factors notably, the integration of combination therapies that address multiple elements of disease pathophysiology, a rise in diabetes and hypertension cases, broader accessibility to healthcare amenities and specialized retinal treatment. This is compounded by the success of clinical trials that underline the effectiveness of new treatment approaches and the maturation of anti-VEGF treatments.
What will be the retinal vein occlusion treatment market size in the future?
The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to cost-effectiveness and reimbursement policies, patient preferences for non-invasive treatments, increased healthcare spending globally, an increasing aging population, and the development of new drugs and therapies. Major trends in the forecast period include gene therapy advancements, nanotechnology for drug delivery, artificial intelligence (AI) in diagnostics, telemedicine and remote monitoring, and the development of patient-centric technologies.
Get your retinal vein occlusion treatment market report here!
What main drivers are fueling expansion in the retinal vein occlusion treatment market?
The escalating numbers of eye conditions globally are projected to fuel the expansion of the retinal vein occlusion treatment market in future. Eye conditions encompass all types of disorders or diseases impacting the eyes or vision, extending from minor issues and infections to critical conditions such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy. The increasing instances of eye conditions are credited to factors like the ageing population and the rising prevalence of diabetes and hypertension. The treatment of retinal vein occlusion focuses on restoring blood flow and minimizing inflammation to avoid loss of vision and manage complications related to this eye condition. As an example, the Centers for Disease Control and Prevention reported in January 2024 that more than 3.4 million Americans aged 40 years and above were afflicted by blindness or vision impairment, a figure expected to double by 2030. Hence, the escalating prevalence of eye conditions is accelerating the growth of the retinal vein occlusion treatment market.
What key areas define the segmentation of the global retinal vein occlusion treatment market?
The retinal vein occlusion treatment market covered in this report is segmented –
1) By Disease Type: Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)
2) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography
3) By Treatment: Anti-Vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Other Treatments
4) By End-User: Hospital And Clinics, Research And Academics, Other End-Users
Subsegments:
1) By Central Retinal Vein Occlusion (CRVO): Non-Ischemic CRVO, Ischemic CRVO
2) By Branch Retinal Vein Occlusion (BRVO): Non-Ischemic BRVO, Ischemic BRVO
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18453&type=smp
Who are the key firms paving the way for growth in the retinal vein occlusion treatment market?
Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.
Which trends are expected to transform the retinal vein occlusion treatment market?
Leading corporations in the retinal vein occlusion treatment market are concentrating on the development of innovative solutions, including interchangeable biosimilars, to better diverse therapy options and increase accessibility for patients. An interchangeable biosimilar is a biological drug closely similar to a pre-existing reference biologic and is deemed an effective alternative to control inflammation and fluid leakage. For example, in May 2024, Indian-based biosimilar production company, Biocon Biologics Limited, won approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf), a biosimilar interchangeable to EYLEA (aflibercept). It serves as a vascular endothelial growth factor (VEGF) inhibitor, tackling a variety of eye-related conditions such as neovascular age-related macular degeneration (wet AMD), macular edema resultant from retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18453
What regions are contributing significantly to the growth of the retinal vein occlusion treatment market?
North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Ophthalmic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ophthalmic-drugs-global-market-report
Ophthalmic Viscoelastic Devices Global Market Report 2024
Ophthalmic Lasers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ophthalmic-lasers-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
